Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Triferic in Healthy Adults
NCT02636049Phase 1Completed
- Sponsor
- Rockwell Medical
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferric pyrophosphate in end stage renal disease (ESRD), sponsored by Rockwell Medical. Primary endpoints: Maximum Drug Concentration of Total Serum Iron at 16 hours and Area Under the Serum Iron Concentration Time Curve From Time Zero to the Time of Last Quantified Concentration at 16 hours. Started Oct 2015; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT02636049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636049.